Status:
NOT_YET_RECRUITING
Quetiapine Versus Trazadone in Women With Postpartum Depression
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Postpartum Depression
Eligibility:
FEMALE
18-45 years
Phase:
EARLY_PHASE1
Brief Summary
Postpartum depression is a serious disorder that affects approximately 17% of women who have recently given birth. Untreated postpartum depression can negatively affect the mother, the infant, and the...
Detailed Description
Design: This double-blind, flexible dosing study aims to compare the effectiveness and tolerability of trazodone and quetiapine in women with PPD. The study will be conducted at the Parkwood Institute...
Eligibility Criteria
Inclusion
- Outpatients between ages 18 and 45 years who are within 6 months of delivering a child and have a DSM-5-TR diagnosis of major depressive disorder (MDD) with peripartum onset, a 17-item Hamilton Depression Rating Scale (HDRS) score of \>18 at both the screening and baseline visits, can communicate in English, and can provide informed consent will be included.
Exclusion
- Women with schizophrenia spectrum or other psychotic disorders, bipolar and related disorders, eating disorders, substance-related and addictive disorders; and those at high risk for suicide (actively suicidal or with a score of ≥ 3 on item #3 on the HDRS) will be excluded. Women with a physical illness that is a contraindication to the use of quetiapine, or who have a history of intolerance or nonresponse to quetiapine will also be excluded.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06546358
Start Date
September 1 2024
End Date
December 1 2025
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Parkwood Institute
London, Ontario, Canada, N6V 0A7